Exploiting the p53 pathway for the diagnosis and therapy of human cancer

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 70, Issue , 2005, Pages 489-497

  Lane, D P ^a  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIINFECTIVE AGENT; DACTINOMYCIN; FLAVOPIRIDOL; FLUOROURACIL; LEPTOMYCIN B; MUTANT PROTEIN; PROTEIN MDM2; PROTEIN P53; ROSCOVITINE; TAXANE DERIVATIVE; TUMOR SUPPRESSOR PROTEIN;

CANCER; CANCER RESEARCH; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DRUG MECHANISM; GENE MUTATION; GENE SEQUENCE; GENE THERAPY; GENETIC TRANSCRIPTION; HEAD AND NECK CANCER; HUMAN; IONIZING RADIATION; METHODOLOGY; PRIORITY JOURNAL; PROTEIN INTERACTION; QUESTIONNAIRE; STAINING; TUMOR BIOPSY; WART VIRUS; ARTICLE; CANCER INHIBITION; CELL HETEROGENEITY; CELL SCREENING; CHEMOTHERAPY; GENE; GENE ACTIVATION; GENETIC STABILITY; MALIGNANT NEOPLASM; NONHUMAN; NUCLEAR EXPORT SIGNAL; P53 GENE; PARADOXICAL DRUG REACTION; SEQUENCE ANALYSIS; TISSUE CULTURE; TRANSCRIPTION ELONGATION; TUMOR CELL;

ANIMALS; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; GENES, P53; HUMANS; MICE; MUTATION; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA;

EID: 33746437470     PISSN: 00917451     EISSN: None     Source Type: Book Series    
DOI: 10.1101/sqb.2005.70.049     Document Type: Conference Paper

References (72)

1. Alvi A.J., Austen B., Weston V.J., Fegan C., MacCallum D., Gianella-Borradori A., Lane D.P., Hubank M., Powell J.E., Wei W., Taylor A.M., Moss P.A., and Stankovic T. 2005. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood 105: 4484.
2. Berkson R.G., Hollick J.J., Westwood N.J., Woods J.A., Lane D.P., and Lain S. 2005. Pilot screening programme for small molecule activators of p53. Int. J. Cancer. 115: 701.
3. Bond G.L., Hu W., and Levine A. 2005a. A single nucleotide polymorphism in the MDM2 gene: From a molecular and cellular explanation to clinical effect. Cancer Res. 65: 5481.
4. _. 2005b. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr. Cancer Drug Targets 5: 3.
5. Bond G.L., Hu W., Bond E.E., Robins H., Lutzker S.G., Arva N.C., Bargonetti J., Bartel F., Taubert H., Wuerl P., Onel K., Yip L., Hwang S.J., Strong L.C., Lozano G., and Levine A.J. 2004. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591.
6. Bottger A., Bottger V., Sparks A., Liu W.L., Howard S.F., and Lane D.P. 1997b. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7: 860.
7. Bottger A., Bottger V., Garcia-Echeverria C., Chene P., Hochkeppel H.K., Sampson W., Ang K., Howard S.F., Picksley S.M., and Lane D.P. 1997a. Molecular characterization of the hdm2-p53 interaction. J. Mol. Biol. 269: 744.
8. Bottger V., Bottger A., Garcia-Echeverria C., Ramos Y.F., van der Eb A.J., Jochemsen A.G., and Lane D.P. 1999. Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene 18: 189.
9. Bottger V., Bottger A., Howard S.F., Picksley S.M., Chene P., Garcia-Echeverria C., Hochkeppel H.K., and Lane D.P. 1996. Identification of novel mdm2 binding peptides by phage display. Oncogene 13: 2141.
10. Bourdon J.C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A., Xirodimas D.P., Saville M.K, and Lane D.P. 2005. p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 19: 2122.
11. Brodsky M.H., Nordstrom W., Tsang G., Kwan E., Rubin G.M., and Abrams J.M. 2000. Drosophila p53 binds a damage response element at the reaper locus. Cell 101: 103.
12. Bykov V.J., Issaeva N., Zache N., Shilov A., Hultcrantz M., Bergman J., Selivanova G., and Wiman K.G. 2005. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J. Biol. Chem. 280: 30384.
13. Bykov V.J., Issaeva N., Shilov A., Hultcrantz M., Pugacheva E., Chumakov P., Bergman J., Wiman K.G., and Selivanova G. 2002. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8: 282.
14. Canadillas J.M., Tidow H., Freund S.M., Rutherford T.J., Ang H.C., and Fersht A.R. 2006. Solution structure of p53 core domain: Structural basis for its instability. Proc. Natl. Acad. Sci. 103: 2109.
15. Cho Y., Gorina S., Jeffrey P.D., and Pavletich N.P. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265: 346.
16. Clarke A.R, Purdie C.A, Harrison D.J, Morris R.G, Bird C.C, Hooper M.L, and Wyllie A.H. 1993. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849.
17. Derry W.B., Putzke A.P., and Rothman J.H. 2001. Caenorhabditis elegans p53: Role in apoptosis, meiosis, and stress resistance. Science 294: 591.
18. Donehower L.A. 2005. p53: Guardian AND suppressor of longevity? Exp. Gerontol. 40: 7.
19. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A., Jr., Butel J.S., and Bradley A. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215.
20. Eischen C.M., Alt J.R., and Wang P. 2004. Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development. Oncogene 23: 8931.
21. Foster B.A., Coffey H.A., Morin M.J., and Rastinejad F. 1999. Pharmacological rescue of mutant p53 conformation and function. Science 286: 2507.
22. Friedler A., Veprintsev D.B., Hansson L.O., and Fersht A.R. 2003. Kinetic instability of p53 core domain mutants: Implications for rescue by small molecules. J. Biol. Chem. 278: 24108.
23. Friedler A., Hansson L.O., Veprintsev D.B., Freund S.M., Rippin T.M., Nikolova P.V., Proctor M.R., Rudiger S., and Fersht A.R. 2002. A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants. Proc. Natl. Acad. Sci. 99: 937.
24. Gojo I., Zhang B., and Fenton R.G. 2002. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and downregulation of Mcl-1. Clin. Cancer Res. 8: 3527.
25. Gomes N.P., Bjerke G., Llorente B., Szostek S.A., Emerson B.M., and Espinosa J.M. 2006. Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program. Genes Dev. 20: 601.
26. Greenblatt M.S., Bennett W.P., Hollstein M., and Harris C.C. 1994. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 54: 4855.
27. Hainaut P., Hernandez T., Robinson A., Rodriguez-Tome P., Flores T., Hollstein M., Harris C.C., and Montesano R. 1998. IARC database of p53 gene mutations in human tumors and cell lines: Updated compilation, revised formats and new visualisation tools. Nucleic Acids Res. 26: 205.
28. Hietanen S., Lain S., Krausz E., Blattner C., and Lane D.P. 2000. Activation of p53 in cervical carcinoma cells by small molecules. Proc. Natl. Acad. Sci. 97: 8501.
29. Hupp T.R., Meek D.W., Midgley C.A., and Lane D.P. 1992. Regulation of the specific DNA binding function of p53. Cell 71: 875.
30. _. 1993. Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res. 21: 3167.
31. Ishioka C., Frebourg T., Yan Y.X., Vidal M., Friend S.H., Schmidt S., and Iggo R. 1993. Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat. Genet. 5: 124.
32. Jeffrey P.D., Gorina S., and Pavletich N.P. 1995. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 267: 1498.
33. Jin S., Martinek S., Joo W.S., Wortman J.R., Mirkovic N., Sali A., Yandell M.D., Pavletich N.P., Young M.W., and Levine A.J. 2000. Identification and characterization of a p53 homologue in Drosophila melanogaster. Proc. Natl. Acad. Sci. 97: 7301.
34. Kotala V., Uldrijan S., Horky M., Trbusek M., Strnad M., and Vojtesek B. 2001. Potent induction of wild-type p53-dependent transcription in tumour cells by a synthetic inhibitor of cyclin-dependent kinases. Cell. Mol. Life Sci. 58: 1333.
35. Knudson A.G. 2001. Two genetic hits (more or less) to cancer. Nat. Rev. Cancer 1: 157.
36. Krummel K.A., Lee C.J., Toledo F., and Wahl G.M. 2005. The C-terminal lysines fine-tune p53 stress responses in a mouse model but are not required for stability control or transactivation. Proc. Natl. Acad. Sci. 102: 10188.
37. Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J., and Pavletich N.P. 1996. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948.
38. Lain S., Midgley C., Sparks A., Lane E.B., and Lane D.P. 1999. An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs. Exp. Cell Res. 248: 457.
39. Lane D.P. and Crawford L.V. 1979. T antigen is bound to a host protein in SV40-transformed cells. Nature 278: 261.
40. Lang G.A., Iwakuma T., Suh Y.A., Liu G., Rao V.A., Parant J.M., Valentin-Vega Y.A., Terzian T., Caldwell L.C., Strong L.C., El-Naggar A.K., and Lozano G. 2004. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119: 861.
41. Leaf C. 2004. Why we're losing the war on cancer (and how to win it). Fortune (March 22, p. 77).
42. Liu W.L., Midgley C., Stephen C., Saville M., and Lane D.P. 2001. Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein. J. Mol. Biol. 313: 711.
43. Lowe S.W. 1995. Cancer therapy and p53. Curr. Opin. Oncol. 7: 547.
44. Lowe S.W. and Sherr C.J. 2003. Tumor suppression by Ink4a-Arf: Progress and puzzles. Curr. Opin. Genet. Dev. 13: 77.
45. Lowe S.W., Schmitt E.M., Smith S.W., Osborne B.A., and Jacks T. 1993. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847.
46. MacCallum D.E., Melville J., Frame S., Watt K., Anderson S., Gianella-Borradori A., Lane D.P., and Green S.R. 2005. Seliciclib ( CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res. 65: 5399.
47. Mantovani F. and Banks L. 2001. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20: 7874.
48. Maxwell S.A., Ames S.K., Sawai E.T., Decker G.L., Cook R.G., and Butel J.S. 1991. Simian virus 40 large T antigen and p53 are microtubule-associated proteins in transformed cells. Cell Growth Differ. 2: 115.
49. Midgley C.A. and Lane D.P. 1997. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15: 1179.
50. Miller L.D., Smeds J., George J., Vega V.B., Vergara L., Ploner A., Pawitan Y., Hall P., Klaar S., Liu E.T., and Bergh J. 2005. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl. Acad. Sci. 102: 13550
51. Miller M., Lubkowski J., Rao J.K., Danishefsky A.T., Omichinski J.G., Sakaguchi K., Sakamoto H., Appella E., Gronenborn A.M., and Clore G.M. 1996. The oligomerization domain of p53: Crystal structure of the trigonal form. FEBS Lett. 399: 166.
52. Moll U.M. and Slade N. 2004. p63 and p73: Roles in development and tumor formation. Mol. Cancer Res. 2: 371.
53. Mummenbrauer T., Janus F., Muller B., Wiesmuller L., Deppert W., and Grosse F. 1996. p53 protein exhibits 3′-to-5′ exonuclease activity. Cell 85: 1089.
54. Munro A.J., Lain S., and Lane D.P. 2005. p53 abnormalities and outcomes in colorectal cancer: A systematic review. Br. J. Cancer 92: 434.
55. Nenutil R., Smardova J., Pavlova S., Hanzelkova Z., Muller P., Fabian P., Hrstka R., Janotova P., Radina M., Lane D.P., Coates P.J., and Vojtesek B. 2005. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J. Pathol. 207: 251.
56. Olive K.P., Tuveson D.A., Ruhe Z.C., Yin B., Willis N.A., Bronson R.T., Crowley D., and Jacks T. 2004. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119: 847.
57. Ollmann M., Young L.M., Di Como C.J., Karim F., Belvin M., Robertson S., Whittaker K., Demsky M., Fisher W.W., Buchman A., Duyk G., Friedman L., Prives C., and Kopczynski C. 2000. Drosophila p53 is a structural and functional homolog of the tumor suppressor p53. Cell 101: 91.
58. O'Shea C.C., Soria C., Bagus B., and McCormick F. 2005. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 8: 61.
59. Raje N., Kumar S., Hideshima T., Roccaro A., Ishitsuka K., Yasui H., Shiraishi N., Chauhan D., Munshi N.C., Green S.R., and Anderson K.C. 2005. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 106: 1042.
60. Smart P., Lane E.B., Lane D.P., Midgley C., Vojtesek B., and Lain S. 1999. Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. Oncogene 18: 7378.
61. Stephen C.W., Helminen P., and Lane D.P. 1995. Characterisation of epitopes on human p53 using phage-displayed peptide libraries: Insights into antibody-peptide interactions. J. Mol. Biol. 248: 58.
62. Tsukada T., Tomooka Y., Takai S., Ueda Y., Nishikawa S., Yagi T., Tokunaga T., Takeda N., Suda Y., and Abe S. 1993. Enhanced proliferative potential in culture of cells from p53-deficient mice. Oncogene 8: 3313.
63. Varley J.M. 2003. Germline TP53 mutations and Li-Fraumeni syndrome. Hum. Mutat. 21: 551.
64. Varley J.M., Thorncroft M., McGown G., Appleby J., Kelsey A.M., Tricker K.J., Evans D.G., and Birch J.M. 1997. A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene. Oncogene 14: 865.
65. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., and Liu E.A. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844.
66. Veprintsev D.B., Freund S.M., Andreeva A., Rutledge S.E., Tidow H., Canadillas J.M., Blair C.M., and Fersht A.R. 2006. Core domain interactions in full-length p53 in solution. Proc. Natl. Acad. Sci. 103: 2115.
67. Vogelstein B., Lane D., and Levine A.J. 2000. Surfing the p53 network. Nature 408: 307.
68. Vojtesek B., Fisher C.J., Barnes D.M., and Lane D.P. 1993. Comparison between p53 staining in tissue sections and p53 proteins levels measured by an ELISA technique. Br. J. Cancer 67: 1254.
69. Wallace-Brodeur R.R. and Lowe S.W. 1999. Clinical implications of p53 mutations. Cell. Mol. Life Sci. 55: 64.
70. Wei C.L., Wu Q., Vega V.B., Chiu K.P., Ng P., Zhang T., Shahab A., Yong H.C., Fu Y., Weng Z., Liu J., Zhao X.D., Chew J.L., Lee Y.L., Kuznetsov V.A., Sung W.K., Miller L.D., Lim B., Liu E.T., Yu Q., Ng H.H., and Ruan Y. 2006. A global map of p53 transcription-factor binding sites in the human genome. Cell 124: 207.
71. Wijnhoven S.W., Kool H.J., van Teijlingen C.M., van Zeeland A.A., and Vrieling H. 2001. Loss of heterozygosity in somatic cells of the mouse. An important step in cancer initiation? Mutat. Res. 473: 23.
72. Xirodimas D.P., Saville M.K., Bourdon J.C., Hay R.T., and Lane D.P. 2004. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 118: 83.